Author of

• 10743

  +

  P1.10 - Poster Session 1 - Chemotherapy (ID 204)

  • Event: WCLC 2013
  • Type: Poster Session
  • Track: Medical Oncology
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/28/2013, 09:30 - 16:30, Exhibit Hall, Ground Level

  • 10745

    +

    P1.10-002 - Comparison of the toxicity and efficacy between topotecan- and belotecan-, a new camptothecin analog, monotherapy for small cell lung cancer : A single institutional experience (ID 156)

    09:30 - 09:30  |  Author(s): H.S. Park
    • Abstract

    Background
    There has been no randomized controlled study for comparing tumor response, toxicity and survival between belotecan- and topotecan- monotherapy in patients with SCLC. To aim of this study is to assess and compare tumor response, toxicity and survival between belotecan- and topotecan- monotherapy in patients with SCLC.Therefore, we try to help physicians to select drugs through a comparison of the efficacy and toxicity for both drugs in this study.

    Methods
    The clinical data of 94 patients treated with belotecan- (n=59, total 188cycles) or topotecan- (n=35, total 65cycles) monotherapy were reviewed retrospectively from September 2003 to December 2011. Hematologic and Nonhematologic toxicities were evaluated according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Statistical significance of Time to progressive disease (TTPD), chemotherapy-specific survival (CSS) and overall survival (OS) between the 2 chemotherapies were evaluated by the Kaplan-Meier analysis.

    Results
    There were no significant differences in baseline characteristics between belotecan- and topotecan- monotherapy except the line of chemotherapy. The overall response rate was 12.7% in patients treated with belotecan monotherapy and 5% in topotecan monotherapy. Thrombocytopenia was developed in 42% and 61.5% of cycles in belotecan- and topotecan- monotherapy, respectively (P = 0.007). In nonhematological toxicities, grade 4 or 5 in lung infection, headache, grade 4 or 5 in elevation of liver enzyme developed in 3.2% and 10.8% (P=0.003), 3.2% and 10.8% (p=0.017), 0.5% and 4.6% (p=0.023) of cycles in belotecan- and topotecan- monotherapy, respectively. The median TTPD, CSS and OS were 14 months and 11.6 months (P=0.646), 10 month and 7 month (P=0.179), 34.5 months and 21.4 months (P=0.914) in belotecan- and topotecan- monotherapy, respectively.

    Conclusion
    In our experience, belotecan monotherapy seemed to be efficient compared with topotecan monotherapy in small cell lung cancer, with acceptable toxicity, especially in thrombocytopenia, severe lung infection and elevation of liver enzyme.